Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Sujay Jadhav_2023
Sujay Jadhav converses about VeraSite, a recently launched subscription-based tool for clinical trial site selection
Shots:  In an insightful interview with PharmaShots, Sujay Jadhav, CEO of Verana Health, discusses VeraSite, a recently launched subscription-based tool for clinical trial site selection   To gather real-world data, Verana Health leverages the VeraQ population health data engine and transforms the structured and unstructured data into curated disease-specific modules called QData   Currently available in the…
October 17, 2023
VIEWPOINTS_Nathan McCutcheon_2023
Nathan McCutcheon shares highlights of Qpex Biopharma’s acquisition by Shionogi
Shots:  Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi   Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline   The acquisition provides Shionogi exclusive development, manufacturing,…
October 16, 2023
VIEWPOINTS_Robert Connelly_2023
Robert Connelly shares the highlights of the post-merger between Elicio Therapeutics & Angion Biomedica Corp.
Shots:  Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies  Robert recapitulates data presented at ASCO…
October 9, 2023
VIEWPOINTS_Samantha Kerr_2023
Samantha Kerr shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)
Shots: Samantha Kerr, Chief Scientific Officer, Merz Aesthetics shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+) Samantha says, for Belotero Balance (+), Merz Aesthetics has already submitted the data as a supplemental Premarket Approval Application (sPMA) with the FDA and plans to submit the data as…
October 5, 2023
VIEWPOINTS_Grant Kim_2023
Grant Kim Shares His Views from the Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Achieving All Three Primary Endpoints
Shots: Grant started by highlighting the characteristics of the AVEIR DR leadless pacemaker and this pacemaker is an effective treatment for people with slower-than-normal heart rhythms He discussed the AVEIR™ DR i2i™ IDE study's design and outcomes, which assessed the safety and performance of the world's first dual-chamber leadless pacemaker. The study effectively met all…
September 19, 2023
VIEWPOINTS_Simon Portsmouth_2023
Simon Portsmouth Shares Insights from P-III Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection
Shots: Simon spoke about the enrollment of the first participant in Japan in the P-III (SCORPIO-PEP) study to evaluate the safety and efficacy of Ensitrelvir for the prevention of symptomatic SARS-CoV-2 infection He mentioned how this study will supplement data from the pivotal SCORPIO-SR trial's P-III segment which showed ensitrelvir's effectiveness in treating mild-to-moderate COVID-19…
September 18, 2023
Load more